AZ’s Farxiga Gets FDA Priority Review For Heart Failure
Moves Ahead of Rival SGLT2 Inhibitors
AstraZeneca has got off to a strong start in 2020, with the FDA granting a fast review for its diabetes drug Farxiga in heart failure and China approving Lokelma for hyperkalemia.
